AbbVie has presented new real-world data on VRAYLAR® (cariprazine) at Psych Congress 2026 in New Orleans, including results from two prospective observational studies in major depressive disorder (MDD)… read more.
A five-year, $3.4 million grant from the National Institutes of Health is powering work by an interdisciplinary team of researchers at The University of Texas at Dallas investigating… read more.
Eisai Co., Ltd. and Biogen Inc. announced that once weekly lecanemab-irmb subcutaneous injection (brand name: LEQEMBI IQLIK) is now available in the U.S. for initiation therapy for early… read more.
Facing major surgery is stressful, but for older adults, unaddressed anxiety and depression can impede physical recovery. A clinical trial led by researchers at Washington University School of… read more.
In the 1970s, psychiatric diagnoses were marked by considerable uncertainty and disagreement. Since then, organisations such as the American Psychiatric Association and the World Health Organization (WHO) have… read more.
Eisai Co., Ltd. and Biogen Inc. announced that the National Medical Products Administration (NMPA) of China has approved the subcutaneous formulation (subcutaneous autoinjector: SC-AI), the anti-amyloid beta (Aβ)… read more.
A multicenter randomized clinical trial led by researchers from the Pain Outcomes Lab at Wake Forest University School of Medicine found that high-frequency spinal cord stimulation significantly reduced pain and… read more.
As Prime Minister Mark Carney prepares to host the inaugural Canada Investment Summit in Toronto this September, a new review co-led by researchers at UBC argues that the… read more.
Three large studies together show that, although the number of people who smoke is declining, people are taking up smoking at a younger age and vaping has increased,… read more.
Emergency Medicine & Intensive Care
Tens of millions of people suffer from traumatic brain injury every year worldwide, with almost 5 million deaths. Yet when it comes to improving clinical outcomes, new research… read more.
Quest Diagnostics announced two new developments for its Quest AD-Detect portfolio of blood-based biomarker tests for Alzheimer’s disease, with the goal of broadening access to quality blood tests… read more.
New research led by the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London, in collaboration with an international partnership of researchers, has, for the first… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
